Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Trans R Soc Trop Med Hyg. 2010 Oct;104(10):684-6. doi: 10.1016/j.trstmh.2010.05.009. Epub 2010 Jun 17.
Sixty-six children presenting to Singa hospital, Sudan with different manifestations of severe Plasmodium falciparum malaria were randomly divided into two well-matched groups (33 in each arm) to receive either intravenous artesunate 2·4 mg/kg at 0, 12, and 24 hours, then daily, or intravenous quinine 20mg/kg initially then 10mg/kg three times a day. There was no significant difference in the fever, parasite clearance, and coma resolution times. Three patients died, one in the artesunate and two in the quinine groups. One patient developed hypoglycaemia following quinine infusion. Thus, artesunate can be used for the treatment of severe falciparum malaria.
66 名在苏丹辛格医院就诊的患有不同临床表现的严重恶性疟疾病例，随机分为两组（每组 33 例），分别接受静脉注射青蒿琥酯 2.4mg/kg，分别在 0、12 和 24 小时，然后每天一次，或静脉注射奎宁 20mg/kg 初始剂量，然后每天三次 10mg/kg。发热、寄生虫清除和昏迷缓解时间无显著差异。有 3 例患者死亡，1 例在青蒿琥酯组，2 例在奎宁组。1 例患者在输注奎宁后出现低血糖。因此，青蒿琥酯可用于治疗严重的恶性疟疾。
